Charles Pritchard, MD, FACR, RhMSUS - Bringing Emerging Therapies Into Motion for Non-Radiographic Axial Spondyloarthritis

episode

CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

NPR News: 09-24-2026 5AM EDT 5 min · 24 Sep 2026 · NPR News Now

Busting Brain Myths: TikTok's Viral Neuroscientist 11 min · 24 Sep 2026 · Today with David McCullagh

Classic Suze School: The Keys to a Successful Relationship 20 min · 24 Sep 2026 · Suze Orman's Women & Money (And Everyone Smart Enough To Listen)

Give Yourself a Year to Try 12 New Things and Embrace Change 39 min · 24 Sep 2026 · The Oprah Podcast

We Investigated the Christian "Scam" Fronted by Tim Tebow 1h 17m · 24 Sep 2026 · Pablo Torre Finds Out

Trump threatens Iran in fiery UN speech. What's next? 14 min · 24 Sep 2026 · The Excerpt

Report any issue

Source

Recorded04 Jan 2023

Publisherc.answersincme.com ↗

Handlerec:13096855

Show notes

Please visit answersincme.com/CUA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in rheumatology discusses treatment options for non-radiographic axial spondyloarthritis (nr-axSpA). Upon completion of this activity, participants should be better able to: Recognize guideline-recommended treatment options used to reduce the burden of non-radiographic axial spondyloarthritis (nr-axSpA) on patients; Describe the clinical impact of approved and late-stage emerging agents for the treatment of nr-axSpA; and Outline clinical considerations for the role of approved and late-stage emerging agents in the treatment landscape of nr-axSpA.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in